238 related articles for article (PubMed ID: 22247228)
1. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients.
Locsey L; Seres I; Sztanek F; Harangi M; Padra J; Kovacs D; Fedor R; Asztalos L; Paragh G
Transplant Proc; 2013; 45(10):3685-7. PubMed ID: 24314997
[TBL] [Abstract][Full Text] [Related]
3. Effect of nutritional status on human paraoxonase-1 activity in patients with chronic kidney disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Koncsos P; Paragh G
Kidney Blood Press Res; 2012; 36(1):310-9. PubMed ID: 23235285
[TBL] [Abstract][Full Text] [Related]
4. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
5. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients.
Varga E; Seres I; Harangi M; Sztanek F; Asztalos L; Lõcsey L; Borbás B; Szegedi J; Kárpáti I; Paragh G
Dis Markers; 2009; 26(3):141-8. PubMed ID: 19597297
[TBL] [Abstract][Full Text] [Related]
6. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis.
Gugliucci A; Kinugasa E; Kotani K; Caccavello R; Kimura S
Clin Chem Lab Med; 2011 Jan; 49(1):61-7. PubMed ID: 20961187
[TBL] [Abstract][Full Text] [Related]
7. Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis.
Zohny SF; El-Fattah MA; Khan JA
Clin Invest Med; 2016 Oct; 39(5):E173-E181. PubMed ID: 27805900
[TBL] [Abstract][Full Text] [Related]
8. PON1 status in haemodialysis patients and the impact of hepatitis C infection.
Horoz M; Aslan M; Selek S; Koylu AO; Bolukbas C; Bolukbas FF; Celik H; Erel O
Clin Biochem; 2007 Jun; 40(9-10):609-14. PubMed ID: 17335792
[TBL] [Abstract][Full Text] [Related]
9. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.
David S; Kümpers P; Hellpap J; Horn R; Leitolf H; Haller H; Kielstein JT
Am J Kidney Dis; 2009 May; 53(5):770-8. PubMed ID: 19268412
[TBL] [Abstract][Full Text] [Related]
11. Main determinants of PON1 activity in hemodialysis patients.
Ribeiro S; do Sameiro Faria M; Mascarenhas-Melo F; Freitas I; Mendonça MI; Nascimento H; Rocha-Pereira P; Miranda V; Mendonça D; Quintanilha A; Belo L; Costa E; Reis F; Santos-Silva A
Am J Nephrol; 2012; 36(4):317-23. PubMed ID: 23007074
[TBL] [Abstract][Full Text] [Related]
12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
13. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study.
Juretić D; Tadijanović M; Rekić B; Simeon-Rudolf V; Reiner E; Baricić M
Croat Med J; 2001 Apr; 42(2):146-50. PubMed ID: 11259735
[TBL] [Abstract][Full Text] [Related]
14. Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients.
Varga Z; Paragh G; Seres I; Kakuk G; Karanyi Z; Karpati I; Matyus J; Csongradi E; Juhasz A; Balla J; Bajnok L
Nephron Clin Pract; 2006; 103(3):c114-20. PubMed ID: 16534235
[TBL] [Abstract][Full Text] [Related]
15. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients.
Rahimi-Ardabili B; Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Naghavi-Behzad M; Ghorashi S; Nezami N
Ren Fail; 2012; 34(9):1123-8. PubMed ID: 22950600
[TBL] [Abstract][Full Text] [Related]
16. Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure.
Varga É; Seres I; Harangi M; Kárpáti I; Koncsos P; Sztanek F; Paragh G
Kidney Blood Press Res; 2012; 35(4):265-72. PubMed ID: 22378349
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease.
Kerkeni M; Addad F; Chauffert M; Chuniaud L; Miled A; Trivin F; Maaroufi K
Clin Biochem; 2006 Aug; 39(8):821-5. PubMed ID: 16875684
[TBL] [Abstract][Full Text] [Related]
18. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease.
Kerkeni M; Letaief A; Achour A; Miled A; Trivin F; Maaroufi K
Clin Biochem; 2009 Jun; 42(9):777-82. PubMed ID: 19233152
[TBL] [Abstract][Full Text] [Related]
20. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
